FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...

Wegovy and Ozempic remain on the FDA's shortages list, despite strenuous efforts ... professionals turning to unapproved versions of GLP-1 drugs as an option for weight loss, saying: "This can ...

The results come just a few weeks after a once-weekly injectable GLP-1 drug CT-388 – also sourced ... one of a lengthening list of pharma companies that are hoping to hit on effective 'me ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has ruled that warnings about the risk should now be added to ...

The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process ...